FDA Smacks Down Vanda's Bid To Block Fanapt Generics
Vanda Pharmaceuticals Inc. cannot use new exclusivity for its schizophrenia medication Fanapt to block generic versions of the product, the U.S. Food and Drug Administration said in a decision released Wednesday....To view the full article, register now.
Already a subscriber? Click here to view full article